These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 34590394

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Agreement between one stage and chromogenic assays in samples from patients receiving recombinant porcine FVIII (Obizur, Susoctocog-alfa).
    Guy S, Bowyer AE, Shepherd MF, Maclean RM, Kitchen S.
    Int J Lab Hematol; 2024 Feb; 46(1):135-140. PubMed ID: 37799011
    [Abstract] [Full Text] [Related]

  • 4. Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A.
    Solms A, Shah A, Berntorp E, Tiede A, Iorio A, Linardi C, Ahsman M, Mancuso ME, Zhivkov T, Lissitchkov T.
    Ann Hematol; 2020 Nov; 99(11):2689-2698. PubMed ID: 32974838
    [Abstract] [Full Text] [Related]

  • 5. Comprehensive laboratory assessment of lonoctocog alfa versus octocog alfa in severe haemophilia A.
    Müller J, Albert T, Klein C, Horneff S, Rühl H, Pötzsch B, Goldmann G, Marquardt N, Oldenburg J.
    Haemophilia; 2024 Aug 20. PubMed ID: 39164802
    [Abstract] [Full Text] [Related]

  • 6. Measuring FVIII activity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clotting and chromogenic assay kits: a two-centre study.
    Hillarp A, Bowyer A, Ezban M, Persson P, Kitchen S.
    Haemophilia; 2017 May 20; 23(3):458-465. PubMed ID: 28198071
    [Abstract] [Full Text] [Related]

  • 7. Comparison of one-stage and chromogenic factor VIII assays to tailor the dose of recombinant factor VIII-Fc fusion protein (rFVIIIFc, efmoroctocog alfa) in adult patients with haemophilia A: Single-centre, real-world experience of surgery.
    Désage S, Nougier C, Meunier S, Chamouard V, Jousselme E, Dargaud Y, Lienhart A.
    Haemophilia; 2024 Mar 20; 30(2):538-544. PubMed ID: 38149726
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Canadian clinical experience on switching from standard half-life recombinant factor VIII (rFVIII), octocog alfa, to extended half-life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada.
    Matino D, Germini F, Chan AKC, Decker K, Iserman E, Chelle P, Edginton AN, Oladoyinbo O, Trinari E, Keepanasseril A, Iorio A.
    Haemophilia; 2024 Mar 20; 30(2):345-354. PubMed ID: 38379181
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Clinical efficacy of simoctocog alfa versus extended half-life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching-adjusted indirect comparison method.
    Kessler CM, Corrales-Medina FF, Mannucci PM, Jiménez-Yuste V, Tarantino MD.
    Eur J Haematol; 2023 Nov 20; 111(5):757-767. PubMed ID: 37587687
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Factor VIII chromogenic assays can be used for potency labeling and postadministration monitoring of N8-GP.
    Pickering W, Hansen M, Kjalke M, Ezban M.
    J Thromb Haemost; 2016 Aug 20; 14(8):1579-87. PubMed ID: 27241682
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors.
    Bowyer A, Kitchen S, Maclean R.
    Haemophilia; 2020 May 20; 26(3):536-542. PubMed ID: 32249990
    [Abstract] [Full Text] [Related]

  • 16. Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review.
    Reding MT, Lalezari S, Kenet G, Di Minno G, Ducore J, Solms A, Shah A, Holme PA, Poulsen LH, Meijer K, Simpson M, Mancuso ME.
    Drugs R D; 2024 Sep 20; 24(3):359-381. PubMed ID: 39162954
    [Abstract] [Full Text] [Related]

  • 17. Estimation of Nuwiq® (simoctocog alfa) activity using one-stage and chromogenic assays-Results from an international comparative field study.
    Tiefenbacher S, Albisetti M, Baker P, Kappert G, Kitchen S, Kremer Hovinga JA, Pouplard C, Scholz U, Ternisien C, Borgvall C, Vicente T, Belyanskaya L, Walter O, Oldenburg J, Nuwiq Field Study Participating Laboratories.
    Haemophilia; 2019 Jul 20; 25(4):708-717. PubMed ID: 31106957
    [Abstract] [Full Text] [Related]

  • 18. The use of the new ReFacto AF Laboratory Standard allows reliable measurement of FVIII:C levels in ReFacto AF mock plasma samples by a one-stage clotting assay.
    Pouplard C, Caron C, Aillaud MF, Ternisien C, Desconclois C, Dubanchet A, Sobas F.
    Haemophilia; 2011 Sep 20; 17(5):e958-62. PubMed ID: 21457408
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of damoctocog alfa pegol prophylaxis in patients with severe haemophilia A: Results of an interventional, post-marketing study.
    Holme PA, Poulsen LH, Tueckmantel C, Maas Enriquez M, Alvarez Román MT, De Cristofaro R.
    Haemophilia; 2024 Mar 20; 30(2):388-394. PubMed ID: 38229269
    [Abstract] [Full Text] [Related]

  • 20. Validation of factor VIII activity for monitoring standard and extended half-life products and correlation to thrombin generation assays.
    Augustsson C, Norström E, Lind V, Martin M, Astermark J, Strandberg K.
    Haemophilia; 2021 May 20; 27(3):494-500. PubMed ID: 33866649
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.